UK BUSINESS AI UNIVERSE: Labs: Neuroscience

Neuroscience

3 labs · 4 models and products Theme: Companies · Generated from this page's data. Click a name to open its panel on the Labs page. Records resting on one source are tagged "one source".

AI for neuroscience applies machine learning to data about the brain, from scans to traces of brain cells found in blood, to understand and detect diseases such as Alzheimer's. The government's AI for Science Strategy notes the field has no "AlphaFold equivalent" yet. Prima Mente, based in London and San Francisco, generates its own biological data and builds foundation models, starting with Alzheimer's (per the site). Its Pleiades models read chemical marks on DNA (the epigenome), and the company reports blood-DNA signals that point to brain-cell damage before symptoms appear.

Context

The AI for Science Strategy says the UK lacks AlphaFold-style breakthroughs in materials science, fluid dynamics and neuroscience. 20 November 2025 gov.uk/government/publications/ai-for-science-stWe don't have AlphaFold equivalents in materials science, fluid dynamics or neuroscience
UKRI cites the IXI Brain Atlas, which uses AI and image analysis, as supporting more than 40 clinical trials. 19 February 2026 gov.uk/government/news/bold-bet-on-ai-to-keep-ukthe IXI Brain Atlas which is supporting more than 40 clinical trials
Prima Mente launched Pleiades, a family of epigenome models with 90 million to 7 billion parameters. 16 July 2025 businesswire.com/news/home/20250716401893/en/Prigenerative transformers (90M, 600M, and 7B parameters)
Prima Mente reports that Pleiades found blood-DNA signatures that signal brain degeneration before symptoms appear. 16 July 2025 businesswire.com/news/home/20250716401893/en/Prisignal neurodegeneration before clinical symptoms appear.
Prima Mente was one of six start-ups given AI Research Resource compute in the Sovereign AI Unit's first round of backing. 16 April 2026 gov.uk/government/news/ai-firms-pioneering-drug-using AI to decode the languages of biology

Key papers

Human whole-epigenome modelling for clinical applications with Pleiades company-hosted preprint (Prima Mente, London and San Francisco; not arXiv or a journal) · July 2025 (per the linked press release)

Labs Round 8 (31 Oct 2026): introduction and facts as the researchers wrote them; "(per the site)" marks a sentence resting on this site's own description of that lab.

Record	What it is	Place	Links	Confidence
CogitatCompanies	Trains its own AI/ML brainwave decoders on EEG data for non-invasive brain-computer interfaces. Models and products (1) Cogitat brainwave decoders 2026-10-31 (as read) offered (as read)Cogitat's AI decoders that turn brain signals from non-invasive EEG headsets into digital commands, built to work across devices without long calibration. Why it is here: trains its own AI/ML brainwave decoders on EEG data for non-invasive brain-computer interfaces (product BIZ-LAB-10013) Key facts and news (1) Awards Ranked first in the NeurIPS "Benchmarks for EEG Transfer Learning" competition (year not given on the page) one source cogitat.io/ Labs Round 8 (31 Oct 2026), from the researchers' rows; one-source items are marked.	London (registered office W8 6SN)	Companies House · cogitat.io/	verified
Cogitat brainwave decodersChips, models and products	Cogitat's AI decoders that turn brain signals from non-invasive EEG headsets into digital commands, built to work across devices without long calibration. offered (as read)Key facts Person-independent decoders trained on real-life EEG data; works across EEG headsets; ranked first in the NeurIPS "Benchmarks for EEG Transfer Learning" competition (cogitat.io, undated)Made by Cogitat · 2026-10-31 (as read)	London (registered office W8 6SN) (via Cogitat)	cogitat.io/	one source
Pleiades (Prima Mente epigenome foundation models)Chips, models and products	Prima Mente's family of epigenome foundation models (90M, 600M, 7B parameters) trained on DNA methylation data to detect Alzheimer's signals in blood. releasedKey facts 90M, 600M and 7B parameters; 1.9 trillion tokens (BioSpace release, 16 Jul 2025); 7B trained on 256 NVIDIA H200 GPUs; 0.89 accuracy for early Alzheimer's and Parkinson's detection, 0.97 with protein tests (company figures; NVIDIA case study, 2 Feb 2026); 32-GPU reserved Nebius H200 cluster raised pre-training throughput by 12%; plan to scale beyond 100B parameters (Nebius customer story, 2026)Made by Prima Mente · 2025-07-16Versions Pleiades → Pleiades-Neuron	London	nvidia.com/en-us/case-studies/primamente/ · biospace.com/press-releases/prima-mente-launches	lab's own pages
Pleiades-NeuronChips, models and products	Prima Mente model that finds very rare DNA fragments shed by brain cells in blood. research (technical report)Key facts Published 24 Oct 2026; built on Pleiades; reported higher sensitivity than a CpA heuristic baseline; found raised neuron-derived cell-free DNA after brain death, in Neuro-ICU patients and in measles patients; access: technical report (PDF)Made by Prima Mente · 2026-10-24Versions Pleiades → Pleiades-Neuron	London	primamente.com/blog/pleiades-neuron/ · primamente.com/research/	lab's own pages
Prima DaedalusChips, models and products	Prima Mente's multi-agent AI workflow that reprocesses published biology experiments into checked training data and tests for its models. research (code not yet public)Key facts Published 24 Sep 2026; three-stage workflow with human approval gates; in one test recovered 41 of 79 author-reported exon-cell-type pairs; code stated to be released "very soon"; access: paper onlyMade by Prima Mente · 2026-09-24	London	primamente.com/blog/prima-daedalus/ · primamente.com/research/	lab's own pages
Prima MenteCompanies	AI biology company that generates its own data and builds biological foundation models, starting with Alzheimer's, Parkinson's and other brain diseases. Profile Founded 2023 (Tech Funding News, trade, single) Founders Hannah Madan — co-founder; Ravi Solanki — Co-Founder; Jonathan Wan — co-founder (names from Tech Funding News; Solanki's title from GOV.UK) Chief executive null (no CEO title found) Hq London (England: London); other_offices: San Francisco; United Arab Emirates Headcount null (team section of the website names 35 people, October 2026; not a stated headcount) What it does An AI biology company that builds foundation models from the human epigenome and brain-related data to find early signs, subtypes and drug targets of brain diseases, starting with Alzheimer's, Parkinson's and ALS. It generates some of its own data and works with NHS and university studies. Research focus biological foundation models; epigenome; neurodegenerative disease (Alzheimer's, Parkinson's, ALS); biomarkers; interpretability (with Goodfire) Models and products Pleiades — whole-epigenome foundation models (90M, 600M and 7B parameters; 1.9 trillion tokens) — 16 July 2025; Pleiades 2 — model combining five biological data modalities, in development on Isambard-AI — June 2026; Prima Daedalus — multi-agent system for training/evaluation data — 24 September 2026; Pleiades-Neuron — detection of neuronal cell-free DNA in blood — 24 October 2026 Customers or partners named Goodfire — interpretability study of Alzheimer's biomarkers — 28 January 2026 — https://www.primamente.com/research/; NVIDIA and Nebius — case study (0.89 accuracy, early-stage Alzheimer's and Parkinson's from blood) — 2 February 2026 — https://www.primamente.com/research/; University of Oxford (READOUT study, NIHR-supported; Prima Mente industry partner) — date null — https://www.primamente.com/research/; Oxford, Imperial and Edinburgh — research collaborations — 16 April 2026 — https://www.gov.uk/government/news/ai-firms-pioneering-drug-discovery-cheaper-supercomputing-and-more-get-first-backing-through-uks-sovereign-ai; collaborators listed on site: Johnson & Johnson, Salk Institute, Dementias Platform UK, Office for Life Sciences, Stanford University and others — October 2026 — https://www.primamente.com/ Papers and awards Longitude Prize on ALS Discovery Award winner — 7 May 2026; "Detecting ultra-rare neuronal cell-free DNA in blood with Pleiades-Neuron" — 24 October 2026; "Automating training and ground truth data for BioAI models and evals" — 24 September 2026 Compute AIRR allocation through Sovereign AI (April 2026); developing Pleiades 2 on Isambard-AI; "nearly 3x speedups" with NVIDIA Blackwell GPUs (telecomtv, June 2026); Nebius reports 1.19 million tokens per second on 16 nodes (via primamente.com research page) Funding total as published 1,400,000 USD ("Total VC raised") — as of 16 April 2026 — https://techfundingnews.com/uks-sovereign-ai-fund-names-7-startups-its-supporting-in-its-first-batch-here-are-the-details/ (trade, single); NVIDIA planned investment October 2026, amount not disclosed Rounds found investors named by Tech Funding News: Beyond Capital, Bluebirds Capital, Episode 1 Ventures, Antler, Octopus Ventures (no dates or amounts); 2026-10-13 — strategic investment (planned) — undisclosed — NVIDIA (already DEAL-LAB-029 / DEAL-LAB-2003) Uk government links Sovereign AI / AIRR compute, one of six firms — 16 April 2026 (already DEAL-LAB-2035); Office for Life Sciences listed as collaborator; SANDBOX study across 21 NHS sites (company research page) Status now Active London company with offices in San Francisco and the UAE; NVIDIA announced a planned minority investment on 13 October 2026. Labs Round 7 deep profile (30 Oct 2026), as the researchers wrote it; confidence: verified (location, models, government compute, NVIDIA); founders list, founding year and funding total single_source. Sources primamente.com/ primamente.com/blog/pleiades-july-2025/ primamente.com/research/ primamente.com/news/ gov.uk/government/news/ai-firms-pioneering-drug- sovereignai.gov.uk/post/our-first-investments telecomtv.com/content/digital-platforms-services techfundingnews.com/uks-sovereign-ai-fund-names- blogs.nvidia.com/blog/uk-ecosystem-deployment/ Models and products (3) Version chainsPleiades → Pleiades-Neuron Pleiades-Neuron 2026-10-24 research (technical report)Prima Mente model that finds very rare DNA fragments shed by brain cells in blood. Prima Daedalus 2026-09-24 research (code not yet public)Prima Mente's multi-agent AI workflow that reprocesses published biology experiments into checked training data and tests for its models. Pleiades (Prima Mente epigenome foundation models) 2025-07-16 releasedPrima Mente's family of epigenome foundation models (90M, 600M, 7B parameters) trained on DNA methylation data to detect Alzheimer's signals in blood. Selected papers (4) Detecting ultra-rare neuronal cell-free DNA in blood with Pleiades-Neuron Prima Mente blog · 24 October 2026 Automating training and ground truth data for BioAI models and evals Prima Mente blog · 24 September 2026 Using Interpretability to Identify a Novel Class of Alzheimer's Biomarkers Goodfire research blog with Prima Mente · 28 January 2026 Human whole-epigenome modelling for clinical applications with Pleiades (Niki, Nalmpantis, Ganbat, Byrne, Kathail … Solanki) Prima Mente preprint Key facts and news (10) Offices London; San Francisco; an emerging office in the United Arab Emirates nebius.com/customer-stories/prima-mente Chief executive Ravi Solanki — CEO and co-founder (physician) biospace.com/press-releases/prima-mente-launches Founders Ravi Solanki — co-founder and CEO; Hannah Madan — co-founder (pharmacology and business background) one source nebius.com/customer-stories/prima-mente Models released Pleiades, 90M/600M/7B parameters, 16 Jul 2025 (BIZ-LAB-10007); Pleiades-Neuron, research post 24 Oct 2026 (BIZ-LAB-10008) Compute Pleiades 7B trained on 256 NVIDIA H200 GPUs (Quantum-2 InfiniBand); 32-GPU reserved Nebius cluster on H200; plan to scale Pleiades beyond 100B parameters on NVIDIA Blackwell nvidia.com/en-us/case-studies/primamente/ Research focus AI that reads DNA sequence, gene expression and epigenetic regulation to understand and tackle brain diseases such as Alzheimer's and Parkinson's Customers and partners Academic collaborators University of Oxford, Hebrew University of Jerusalem, University of Gothenburg (Jul 2025); Goodfire (interpretability, Jan 2026); NVIDIA and Nebius (compute) one source primamente.com/pleiades.pdf Key facts Company figures: 0.89 accuracy for early Alzheimer's and Parkinson's detection from blood, 0.97 with protein tests; 1.9 trillion training tokens one source nvidia.com/en-us/case-studies/primamente/ Customers and partners Nebius (Scaling Pleiades customer story, June 2026: pre-training throughput up 12% to 1.19 million tokens per second on 16 nodes); NVIDIA case study (2 Feb 2026); Goodfire interpretability study on Alzheimer's biomarkers (28 Jan 2026); clinical studies SANDBOX (21 NHS sites, target over 1,000 patients) and READOUT (led by University of Oxford) one source primamente.com/research/ Models released Pleiades (16 Jul 2025; 90M, 600M, 7B), Prima Daedalus (24 Sep 2026), Pleiades-Neuron (24 Oct 2026); Nebius story describes scaling from 7B toward more than 100B parameters one source primamente.com/research/ Labs Round 8 (31 Oct 2026), from the researchers' rows; one-source items are marked.	London	primamente.com/ · blogs.nvidia.com/blog/uk-ecosystem-deployment/ · primamente.com/news/ · find-and-update.company-information.service.gov.	verified
Stanhope AICompanies · also on Software and tools	UCL spin-out building AI that makes decisions on its own, modelled on how the brain works.agentic AI Models and products (1) Real World Model (Stanhope AI) 2026-02-12 in testing (drones and robotics)Stanhope AI's on-device AI framework based on active inference, a neuroscience theory, being tested in autonomous drones and robots. Why it is here: builds its own AI models from active inference and the Free Energy Principle; co-founded by computational neuroscientist Rosalyn Moran and neurobiologist Karl Friston; UCL and King's College London spin-out	London	Companies House · uktech.news/ai/stanhope-funding-ai-human-brains- · find-and-update.company-information.service.gov. · find-and-update.company-information.service.gov. · mmc.vc/portfolio/	verified